Pencil Beam Scanning Proton Therapy Research Articles

Feasibility study of a plastic scintillating plate-based treatment beam fluence monitoring system for use in pencil beam scanning proton therapy.

The purpose of this study was to describe a plastic scintillating plate-based gantry-attachable dosimetry system for pencil beam scanning proton therapy to monitor entrance proton beam fluence, and to evaluate the dosimetric characteristics of this system and its feasibility for clinical use. The dosimetry system, consisting of a plastic scintillating plate and a CMOS camera, was attached to a dedicated scanning nozzle and scintillation during proton beam irradiation was recorded. Dose distribution was calculated from the accumulated recorded frames. The dosimetric characteristics (energy dependency, dose linearity, dose rate dependency, and reproducibility) of the gantry-attachable dosimetry system for use with therapeutic proton beams were measured, and the feasibility of this system during clinical use was evaluated by determining selected quality assurance items at our institution. The scintillating plate shortened the range of the proton beam by the water-equivalent thickness of the plate and broadened the spatial profile of the single proton spot by 11% at 70MeV. The developed system functioned independently of the beam energy (<1.3%) and showed dose linearity, and also functioned independently of the dose rate. The feasibility of the system for clinical use was evaluated by comparing the measured quality assurance dose distribution to that of the treatment planning system. The gamma passing rate with a criterion of 3%/3mm was 97.58%. This study evaluated the dosimetric characteristics of a plastic scintillating plate-based dosimetry system for use with scanning proton beams. The ability to account for the interference of the dosimetry system on the therapeutic beam enabled offline monitoring of the entrance beam fluence of the pencil beam scanning proton therapy independent of the treatment system with high resolution and in a cost-effective manner.

Proceedings to the 6th Annual Conference of the Particle Therapy Cooperative Group North America (PTCOG-NA): 14-16 October 2019, Hosted by Miami Cancer Institute, part of Baptist Health South Florida, Miami, FL, USA.

Proceedings to the 6th Annual Conference of the Particle Therapy Cooperative Group North America (PTCOG-NA): 14-16 October 2019, Hosted by Miami Cancer Institute, part of Baptist Health South Florida, Miami, FL, USA.

An optimized approach for robust spot placement in proton pencil beam scanning

Maintaining a sharp lateral dose falloff in pencil beam scanning (PBS) proton therapy is crucial for sparing organs at risk (OARs), especially when they are in close proximity to the target volume. The most common approach to improve lateral dose falloff is through the use of physical beam shaping devices, such as brass apertures or collimator based systems. A recently proposed approach focuses on proton beam spot placements, moving away from traditional grid-based placements to concentric-contours based schemes. This improves lateral dose falloff in two ways: (1) by better conforming all spots to the tumor boundary and (2) allowing for ‘edge enhancement’, where boundary spots deliver higher fluence than more central spots, thereby creating a steeper lateral dose falloff. However, these benefits come at the expense of maintaining uniformity of spot distribution inside the target volume. In this work we have developed a new optimized spot placement scheme that provides robust spot distributions inside the target. This approach achieves the boundary conformity of a concentric-contours based approach and uses a fast-iterative method to distribute the interior spots in a highly uniform fashion in an attempt to improve both the lateral dose falloff and uniformity. Furthermore, we quantified the impact of this new approach through direct comparison with grid, contour, and hybrid spot placements schemes, showing improvements for this new approach. The results were validated in homogeneous medium for two different target shapes having concave and convex geometry.

Optimal Target Delineation and Treatment Techniques in the Era of Conformal Photon and Proton Breast and Regional Nodal Irradiation

PurposeRegional nodal irradiation improves disease-free and distant disease–free survival in patients with high-risk breast cancer (BC). Trials demonstrating this used 2- or 3-dimensional conformal radiation therapy (2-dimensional or 3-dimensional [3D] conformal radiotherapy [CRT]) fields based on bony anatomy. Modern volumetric-modulated arc therapy (VMAT) and pencil beam scanning proton therapy (PBSPT) may underdose regional nodes (RNs) not contoured but covered by 3D CRT. Multiple atlases guide modern treatment planning. This study addresses the risk of underdosing when relying on published atlases and treating with 3D CRT, VMAT, and PBSPT. Methods and MaterialsTargets per the Radiation Therapy Oncology Group (RTOG), European Society for Radiotherapy and Oncology (ESTRO), and Radiotherapy Comparative Effectiveness Consortium (RADCOMP) atlases were contoured on a representative patient CT scan. 3D CRT plans based on anatomic borders and VMAT and PBSPT plans for each set of target volumes were generated. Positron emission tomography/computed tomography (PET/CT) scans were reviewed. CT-positive and 18F-fluorodeoxyglucose (18F-FDG)–avid RNs (n = 389) were mapped from 102 patients with locally advanced (n = 51; median 2; range, 1-8 nodes) and metastatic (n = 51; median 4; range, 1-19 nodes) BC: axillary (AX; n = 284), supraclavicular (SCV; n = 60), and internal mammary nodal (IMN; n = 45). 18F-FDG-avid RNs falling within the 95% isodose line were considered adequately covered. Results3D CRT plans provided excellent RN coverage. Low AX nodes were covered (≥99%) in all plans. Underdosing of 18F-FDG–avid RNs falling in the high AX (78%-92%), SCV (52%-75%), and IMN (84%-89%) volumes was observed following the RTOG and ESTRO atlases for VMAT and PBSPT plans. Use of the RADCOMP atlas provided coverage of these areas (89%-100%) with slightly increased heart and lung doses. Atlas guided VMAT/PBSPT plans provided cumulative nodal coverage as follows: ESTRO (89%/88%), RTOG (93%/91%), and RADCOMP (98%/96%). ConclusionsVMAT and PBSPT for regional nodal irradiation in patients with high-risk BC risks underdosage in the high AX, SCV, and IMN nodal regions unless comprehensive target delineation is performed.

Trimmer sequencing time minimization during dynamically collimated proton therapy using a colony of cooperating agents

The dynamic collimation system (DCS) can be combined with pencil beam scanning proton therapy to deliver highly conformal treatment plans with unique collimation at each energy layer. This energy layer-specific collimation is accomplished through the synchronized motion of four trimmer blades that intercept the proton beam near the target boundary in the beam’s eye view. However, the corresponding treatment deliveries come at the cost of additional treatment time since the translational speed of the trimmer is slower than the scanning speed of the proton pencil beam. In an attempt to minimize the additional trimmer sequencing time of each field while still maintaining a high degree of conformity, a novel process utilizing ant colony optimization (ACO) methods was created to determine the most efficient route of trimmer sequencing and beamlet scanning patterns for a collective set of collimated proton beamlets. The ACO process was integrated within an in-house treatment planning system optimizer to determine the beam scanning and DCS trimmer sequencing patterns and compared against an analytical approximation of the trimmer sequencing time should a contour-like scanning approach be assumed instead. Due to the stochastic nature of ACO, parameters where determined so that they could ensure good convergence and an efficient optimization of trimmer sequencing that was faster than an analytical contour-like trimmer sequencing. The optimization process was tested using a set of three intracranial treatment plans which were planned using a custom research treatment planning system and were successfully optimized to reduce the additional trimmer sequencing time to approximately 60 s per treatment field while maintaining a high degree of target conformity. Thus, the novel use of ACO techniques within a treatment planning algorithm has been demonstrated to effectively determine collimation sequencing patterns for a DCS in order to minimize the additional treatment time required for trimmer movement during treatment.

Feasibility study of utilizing XRV-124 scintillation detector for quality assurance of spot profile in pencil beam scanning proton therapy

PurposeThe purpose of the current study is to (i) investigate the feasibility of utilizing the XRV-124 – a cone-shaped scintillation detector – to measure the spot size and spot position in pencil beam scanning proton therapy, and (ii) compare the spot sizes acquired by the XRV-124 with that of the widely used Lynx detector. MethodsSpot position was tested by delivering a map of 30 spots at different locations to the XRV-124. Spot position test included energies 70–210 MeV. Spot size measurements were performed at the isocenter using the XRV-124 and Lynx detectors for a total of 32 energies (70–225 MeV at an increment of 5 MeV) at four cardinal gantry angles. ResultsThe position (X, Y, and Z) of the radiation isocenter was within ±0.3 mm. For spots placed on the horizontal (X) and longitudinal (Y) axes of the spot map, both the X and Y locations of the spots were within ±0.5 mm. The spots placed diagonally in the map showed a higher deviation (±0.9 mm). In evaluating spot sizes acquired using the XRV-124 vs. Lynx, the results from the XRV were found to be slightly higher but within 0.2 mm for energies ≥130 MeV and within 0.4 mm for energies <130 MeV. ConclusionsIt is feasible to utilize the XRV-124 to perform the quality assurance of position and size of a pencil proton beam around the radiation isocenter but within the usable XRV-124 cone area.

Risk of brainstem necrosis in pediatric patients with central nervous system malignancies after pencil beam scanning proton therapy

Background: Radiation therapy (RT) plays an important role in management of pediatric central nervous system (CNS) malignancies. Centers are increasingly utilizing pencil beam scanning proton therapy (PBS-PT). However, the risk of brainstem necrosis has not yet been reported. In this study, we evaluate the rate of brainstem necrosis in pediatric patients with CNS malignancies treated with PBS-PT.Material and methods: Pediatric patients with non-hematologic CNS malignancies treated with PBS-PT who received dose to the brainstem were included. All procedures were approved by the institutional review board. Brainstem necrosis was defined as symptomatic toxicity. The actuarial rate was analyzed by the Kaplan Meier method.Results: One hundred and sixty-six consecutive patients were reviewed. Median age was 10 years (range 0.5–21 years). Four patients (2.4%) had prior radiation. Median maximum brainstem dose in the treated course was 55.4 Gy[RBE] (range 0.15–61.4 Gy[RBE]). In patients with prior RT, cumulative median maximum brainstem dose was 98.0 Gy [RBE] (range 17.0–111.0 Gy [RBE]). Median follow up was 19.6 months (range, 2.0–63.0). One patient who had previously been treated with twice-daily radiation therapy and intrathecal (IT) methotrexate experienced brainstem necrosis. The actuarial incidence of brainstem necrosis was 0.7% at 24 months (95% CI 0.1–5.1%).Conclusion: The rate of symptomatic brainstem necrosis was extremely low after treatment with PBS-PT in this study. Further work to clarify clinical and dosimetric parameters associated with risk of brainstem necrosis after PBS-PT is needed.

P14.75 Active beam scanning proton therapy radiosurgery: early outcomes

Abstract BACKGROUND Stereotactic radiosurgery (SRS) is an important treatment option for intracranial lesions and several photon-SRS techniques have been developed. Proton therapy (PT) has special characteristics that allow normal tissues to be spared better as well as greater homogeneity than with the use of photons, but limited data are available for proton-SRS. Nowadays, PT-SRS is delivered only with passive scattering technique while active pencil beam scanning (PBS) that is considered the most advanced proton technique has not been reported for SRS treatments yet. Here we report early clinical outcomes of PBS PT SRS. MATERIAL AND METHODS Between June 2017 and January 2019, 14 patients (pts) with 20 lesions underwent PBS PT SRS at our institution. Median age was 62 years (range, 28–87). Median Karnofsky performance status was 90 (range, 70–100). Six were male. Tumors included 16 meningiomas (MG) and 4 vestibular schwannomas (VS). Median GTV was 1.05 cc (range, 0.2–2.71). Dose prescription was 12 Gy radiobiologic equivalent (RBE) in one fraction for VS and 15 GyRBE in one fraction for MG. Pts were immobilized using a frameless system: Type-S proton overlay and Type-S proton mask (CIVCO medical solutions, Kalona, IA, USA) together with Moldcare headrest (Q-Fix systems, Avondale, PA, USA). All pts were treated with PBS PT using 2–3 fields with single field optimization technique, and using min-max robust robust optimization (2 mm setup errors, 3.5% range uncertainties), with a Monte Carlo algorithm and 1 mm grid size. Toxicity was assessed using Common Terminology Criteria for Adverse Events version 4.0. RESULTS Median follow-up (FU) was 9 months (range, 3–22). All pts completed the treatment with excellent compliance and no side effects were registered during the procedure. Registered acute side effects include grade 1 (14%) fatigue, grade 2 (7%) headache, and grade 2 (28%) alopecia. There were no grade 3 or higher acute toxicities. Registered late side effects include grade 1 (7%) headache, and grade 1 (14%) alopecia. There were no grade 3 or higher late toxicities. Currently, absolute tumor control is 100% regardless the type of tumor. Despite the short FU radiological reduction was registered in 9 lesions (45%). CONCLUSION PBS PT SRS is a feasible and safe treatment in pts with MG or VS. A high radiological response rate was observed. Longer FU is necessary to assess definitive safety and efficacy.

Concurrent External Thermal Therapy and Pencil Beam Scanning Proton Therapy or Photon/Electron Therapy for Recurrent Breast Cancer: Early Outcomes and Toxicity

The combination of external thermal therapy (ETT) and external beam radiation therapy (EBRT) for the treatment of patients with recurrent breast cancer is efficacious and well-tolerated. Traditionally, this has been accomplished with photon and/or electron radiation techniques. While pencil beam scanning proton therapy (PBS-PT) may reduce dose to critical nearby organs, concern has arisen for a higher rate of acute skin toxicity due to reduced skin sparing with particle therapy. We hypothesized that acute/subacute toxicity, local control, and overall survival in women undergoing reirradiation with EBRT via PBS-PT or electron/photon (E/PRT) would be similar in patients treated for recurrent breast cancer. We evaluated women with recurrent breast cancer treated with EBRT+ETT between the years 2014 - 2018. Forty women with 41 treated lesions met inclusion criteria, of which 22 (55%) were white and 16 (40%) black. Median age was 63 years (range 34-93), 14 (35%) patients were metastatic at diagnosis and 10 (25%) patients received treatment with PBS-PT. Median RT dose was 50 Gy (range 20-70.2). Patients received a median of 10 ETT treatments (range, 2-18) usually given twice weekly to a goal temperature of 40-43 degrees Celsius for a duration of 45-60 minutes per session. Water bolus temperature was 39-40 degrees Celsius. Acute radiation dermatitis was assessed based on CTCAE 4.0. Chi-square was used to compare variables and Kaplan-Meier estimates were used to calculate local control. At a median follow up of 15 months for E/PRT and 17 months for PBS-PT, there were a total of 12 failures (39%) in the E/PRT group and 1 failures (10%) in the PBS-PT group (p=0.09). Median time to local failure was 15 mos vs. 22 mos for E/PRT and PBS-PT, respectively. One and 2-year local control (LC) was 51% and 36% vs. 88% and 88% in the E/PRT and PBS-PT groups, respectively (p=0.07). Acute grade ≥2 radiation dermatitis was present in 58% (n=18/31) vs. 50% (n=5/10) of patients receiving E/PRT and PBS-PT, respectively. There were no acute/subacute grade 4+ toxicities with either modality of EBRT+ETT. Our series demonstrates that women with recurrent breast cancer undergoing reirradiation with PBS-PT + ETT had similar rates of acute radiation dermatitis when compared to women undergoing reirradiation with E/PRT. Additionally, local control was excellent in this group with only one local failure, with a trend toward improved local control in PBS-PT compared to E/PRT. Larger numbers of patients and longer maturation of our results is warranted to evaluate outcomes and late toxicity in this challenging disease setting.

Towards the Clinical Implementation of Pencil Beam Scanned Proton Therapy (PBS-PT) for Thoracic Indications: A Comprehensive 4D Robustness Evaluation Based on Patient and Machine Specific Information

Due to anticipated clinical benefits, thoracic tumors are potential future indications for PBS-PT. However, the concern of plan robustness as a result of motion hamper its clinical implementation. Here we present a comprehensive evaluation of different planning strategies based on patient and machine specific data in order to define optimal PBS-PT protocols for lung and esophageal tumors. This study includes 3 non-small cell lung and 3 esophageal cancer patients with a planning as well as 5 weekly repeated 4DCTs available. For all patients, the CTV volume and motion were monitored throughout the treatment course. Layered rescanned (5 times) 3D and 4D robust optimized PBS-PT plans were created, and approved clinically. These plans were then delivered in dry runs at our proton facility to obtain machine log files, and subsequently evaluated through our 4D robustness evaluation method (4DREM). The 4DREM assesses the plan robustness for the combination of (1) setup and range errors, (2) machine errors, (3) anatomy changes, (4) breathing motion, and (5) interplay effects. The disturbing effects (2), (3), (4), (5) are considered by calculating subplan doses on particular 4DCT phases and performing 4D dose accumulation in all 4DCTs. The subplans were split from the nominal plan by retrieving log files information. For each evaluated plan, 14 4D accumulated scenario dose distributions were obtained, representing 14 possible full fractionated treatment courses. Only small differences in V95(CTV) between nominal and voxel-wise worst-case dose distributions were observed for all 3D / 4D robust optimized plans (consistently ≥ 99.89 %). Similarly, averaged Dmean(lungs-GTV) over all scenarios considered within the 4DREM changed only slightly (Table 1). For 6 patients with lung / esophageal cancer, our 3D / 4D PBS-PT planning protocol showed to be clinically suitable. After confirming these results in an extended patient cohort, we will proceed to investigate less conservative, more conformal planning strategies. The experience gained through comprehensive robustness evaluations based on patient and machine specific data is essential for the definition of optimal PBS-PT protocols for patients with thoracic tumors.Abstract 3762; Table 1Patient characteristics (mean ± SD volume and motion variations) and plan statisticsLungPt. 1Pt. 2Pt. 3Volume [cm3]108.2 ± 16.254.6 ± 5.755.6 ± 2.9Motion [mm]3.9 ± 0.84.6 ± 1.43.8 ± 1.23D4D3D4D3D4DDmean(lungs-GTV) [GyRBE] Nominal9.4010.478.497.359.078.47 Scenarios9.8310.688.617.598.927.96EsophagusPt. 4Pt. 5Pt. 6Volume [cm3]367.4 ± 14.0133.6 ± 10.3209.9 ± 2.6Motion [mm]6.5 ± 0.96.5 ± 0.73.1 ± 0.63D4D3D4D3D4DDmean(lungs-GTV) [GyRBE] Nominal4.304.281.381.411.911.98 Scenarios4.354.531.521.641.972.00 Open table in a new tab

Experimental Validation of a Log File-Based Dose Reconstruction and Accumulation for 4D Adaptive Pencil Beam Scanned Proton Therapy

Experimental Validation of a Log File-Based Dose Reconstruction and Accumulation for 4D Adaptive Pencil Beam Scanned Proton Therapy

Effect of Prospective Use of Radiobiologic Effect (RBE) Modeling in Treatment Planning on Magnetic Resonance Imaging (MRI) Radiation Related Changes (RRC) in Pediatric Patients with Brain Tumors Treated with Pencil Beam Scanning Proton Therapy (PBS)

Effect of Prospective Use of Radiobiologic Effect (RBE) Modeling in Treatment Planning on Magnetic Resonance Imaging (MRI) Radiation Related Changes (RRC) in Pediatric Patients with Brain Tumors Treated with Pencil Beam Scanning Proton Therapy (PBS)

Deep Learning Based on Radiomics Features Dataset to Predict the Outcome of Skull-Base Chordomas Patients Treated with Pencil Beam Scanning Proton Therapy

Deep Learning Based on Radiomics Features Dataset to Predict the Outcome of Skull-Base Chordomas Patients Treated with Pencil Beam Scanning Proton Therapy

Concurrent Superficial Thermal Therapy and Pencil Beam Scanning Proton Therapy: Initial Clinical Experience and Safety Profile

Concurrent Superficial Thermal Therapy and Pencil Beam Scanning Proton Therapy: Initial Clinical Experience and Safety Profile

Deep Locoregional Thermal Therapy Concurrent with Pencil Beam Scanning Proton Therapy: Initial Report of Safety and Feasibility

Deep Locoregional Thermal Therapy Concurrent with Pencil Beam Scanning Proton Therapy: Initial Report of Safety and Feasibility

The REACT-Study - a Comprehensive Data Set of REpeated 4D CTs and Cbcts to Prepare for Pencil Beam Scanned Proton Therapy (PBS-PT) in Lung and Esophagus Patients

The REACT-Study - a Comprehensive Data Set of REpeated 4D CTs and Cbcts to Prepare for Pencil Beam Scanned Proton Therapy (PBS-PT) in Lung and Esophagus Patients

JP4-039-Induced Amelioration of Mucositis and Abscopal Bone Marrow Suppression in Fanconi Anemia Fanca-/- Mice during Pencil Beam Scanning Proton Therapy

JP4-039-Induced Amelioration of Mucositis and Abscopal Bone Marrow Suppression in Fanconi Anemia Fanca-/- Mice during Pencil Beam Scanning Proton Therapy

Dynamic beam current control for improved dose accuracy in PBS proton therapy

The step-and-shoot method of pencil beam scanning delivers the dose on a 3D grid in the target volume, with one dimension defined by the proton energy. While the dose per pencil beam may vary substantially within an iso-energy layer, the beam current typically remains constant. In this static operation mode, the inherent latency of the beam switch-off mechanism results in a lower limit for the deliverable spot dose, which may prevent the application of some of the low-weighted spots prescribed by the treatment planning system. To overcome this limitation, we introduced dynamic beam current control at the PSI Gantry 2, an innovative new approach successfully commissioned and in clinical operation since fall 2017. The control system was enhanced with a direct link to the vertical deflector located at the centre of the cyclotron. This connection allows much faster beam current changes (~0.1 ms) and hence opens up the possibility of dynamically reducing the current for individual low-dose spots. We demonstrate that with this new dynamic operation mode, all spots are delivered as planned without compromising treatment time. We show by two independent and complementary methods that the delivered dose distribution is improved.

Temporal lobe sparing radiotherapy with photons or protons for cognitive function preservation in paediatric craniopharyngioma

Background and purposeReducing radiation exposure to the temporal lobes could be beneficial to preserve cognitive function in paediatric brain tumour patients. The distribution of doses to brain substructures associated with cognition (BSCs) both within and outside of the temporal lobe have not been reported. The aim of this study was therefore to investigate temporal lobe sparing photon vs. proton therapy for paediatric suprasellar tumours. Material and methodsData from ten anonymized craniopharyngioma patients were used in this study. Temporal lobe sparing volumetric modulated arc therapy (VMAT) and pencil beam scanning (PBS) proton therapy plans were optimized to maintain consistent target metrics as in the delivered double scattering proton therapy (DSPT) plans. Thirty BSCs were delineated, including temporal lobe substructures (i.e. amygdala, hippocampus, entorhinal cortex). The dose/volume fractions to each BSC were analysed, and intelligence quotient (IQ) as well as memory scores were estimated to compare the different modalities. ResultsThe exposed volumes of the temporal lobes and their substructures were consistently reduced with PBS compared to DSPT and VMAT, e.g. the left hippocampus V10Gy from 100% (VMAT) or 41% (DSPT) to 5% with PBS (p = 0.002). Some of the ventricular substructures were better spared with VMAT compared to both proton modalities. The reduced doses to the temporal lobes achieved with PBS translated into improved predicted memory outcomes, but not for the estimated IQ. ConclusionThe irradiated volumes of temporal lobe BSCs were consistently the lowest with PBS, whereas the model-based estimates of cognitive outcomes were less consistent.

Radiation-induced optic neuropathy after pencil beam scanning proton therapy for skull-base and head and neck tumours.

To assess the radiation-induced optic neuropathy (RION) prevalence, following high dose pencil beam scanning proton therapy (PBSPT) to skull base and head and neck (H&N) tumours. Between 1999 and 2014, 216 adult patients, median age 47 years (range, 18-77), were treated with PBS PT for skull base or H&N malignancies, delivering ≥45 GyRBE to the optic nerve(s) (ON) and/or optic chiasma (OC). The median administered dose to the planning target volume was 74.0 GyRBE (range, 54.0-77.4). The median follow-up was 5.3 years (range, 0.8-15.9). RION was observed in 14 (6.5%) patients at a median time of 13.2 months (range, 4.8-42.6) following PBSPT. Most (92.9%) of RION were symptomatic. Most affected patients (11/14; 79%) developed unilateral toxicity. Grade 4, 3, 2 and 1 toxicity was observed in 10, 2, 1 and 1 patients, respectively. On univariate analyses, age (<70 vs ≥70 years; p < 0.0001), hypertension (p = 0.0007) and tumour abutting the optic apparatus (p = 0.012) were associated with RION. OC's V60 GyRBE was of border line significance (p = 0.06). None of the other evaluated OC-ON dose/volume metrics (Dmax, Dmean, V40-60) were significantly associated with this complication. These data suggest that high-dose PBS PT for skull base and H&N tumours is associated with a low prevalence of RION. Caution should be however exercised when treating elderly/hypertensive patients with tumours abutting the optic apparatus. This is the first study reporting the risk of developing RION following proton therapy with PBS technique, demonstrating the safety of this treatment.